iTeos Therapeutics, Inc. (ITOS)
Data as of , from SEC Form 4 filings.
See up to 3 months of ITOS. The 7-day demo opens the 1M and 3M ranges and puts ITOS on your watchlist.
Start 7-day demoLatest ITOS insider trades
About iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. is an SEC registrant, filing under CIK 0001808865, classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
ITOS Form 4 activity by transaction type, last 90 days
No Form 4 activity for ITOS in the last 90 days.
ITOS insider transactions (Form 4)
3612 Form 4 filings on record, the earliest from Nov 20, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michel Detheux - Officer | Other | Common Stock | 153,903 | - | - | |
| Michel Detheux - Officer | Other | Common Stock | 94,027 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 14,185 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 444,815 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 94,336 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 50,128 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 17,544 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 185,000 | - | - | |
| Michel Detheux - Officer | Derivative | Stock Option (Right to Buy) | 52,700 | - | - | |
| Matthew Call - Officer | Other | Common Stock | 161,898 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 9,063 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 135,937 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 41,694 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 66,170 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 17,074 | - | - | |
| Matthew Call - Officer | Derivative | Stock Option (Right to Buy) | 146,835 | - | - | |
| David K. Lee | Derivative | Stock Option (Right to Buy) | 21,141 | - | - | |
| David K. Lee | Derivative | Stock Option (Right to Buy) | 23,625 | - | - | |
| Yvonne McGrath - Officer | Other | Common Stock | 46,300 | - | - | |
| Yvonne McGrath - Officer | Derivative | Stock Option (Right to Buy) | 91,000 | - | - | |
| Yvonne McGrath - Officer | Derivative | Stock Option (Right to Buy) | 69,069 | - | - | |
| Yvonne McGrath - Officer | Derivative | Stock Option (Right to Buy) | 16,054 | - | - | |
| David Feltquate - Officer | Other | Common Stock | 47,000 | - | - | |
| Matthew Gall - Officer | Other | Common Stock | 89,429 | - | - | |
| Matthew Gall - Officer | Derivative | Stock Option (Right to Buy) | 9,063 | - | - | |
| Matthew Gall - Officer | Derivative | Stock Option (Right to Buy) | 135,937 | - | - | |
| Matthew Gall - Officer | Derivative | Stock Option (Right to Buy) | 42,388 | - | - | |
| Matthew Gall - Officer | Derivative | Stock Option (Right to Buy) | 8,123 | - | - | |
| Matthew Gall - Officer | Derivative | Stock Option (Right to Buy) | 252,135 | - | - | |
 David Hallal | Derivative | Stock Option (Right to Buy) | 25,140 | - | - | |
| David Hallal | Derivative | Stock Option (Right to Buy) | 146,160 | - | - | |
 Ann D. Rhoads | Derivative | Stock Option (Right to Buy) | 27,178 | - | - | |
| MPM BioVentures 2014, L.P. | Open-market sale | Common Stock | 630,191 | $8.06 | $5.08M | |
| Ansbert Gadicke | Open-market sale | Common Stock | 1,031,931 | $8.06 | $8.32M | |
| David Feltquate - Officer | Grant or award | Common Stock | 47,000 | $0.00 | - | |
| Matthew Gall - Officer | Open-market purchase | Common Stock | 5,000 | $7.73 | $39K |
ITOS insider trading FAQ
What is the latest insider trade for ITOS?
iTeos Therapeutics, Inc. (ITOS) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-08-29. The full record for ITOS runs to 12 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ITOS stock?
No insider purchases of ITOS were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling ITOS stock?
No insider sales of ITOS were filed in the last 90 days. 2 sales are on record for this company.
Where can I see ITOS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ITOS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michel Detheux view on EDGAR
- - Matthew Call view on EDGAR
- - David K. Lee view on EDGAR
- - Yvonne McGrath view on EDGAR
- - David Feltquate view on EDGAR
- - Matthew Gall view on EDGAR
- - David Hallal view on EDGAR
- - Ann D. Rhoads view on EDGAR
- - MPM BioVentures 2014, L.P. view on EDGAR
- - Ansbert Gadicke view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ITOS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ITOS with a 7-day demo
- ITOS on your watchlist
- Every ITOS Form 4 filing on record
- Up to 3 months of ITOS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
